Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | FURIN | P09958 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21565500 | 0.87 | CHKA (0.54) | HRH3SLC16A3CHKAHRH4 | |
| SCHEMBL30229943 | 0.87 | CHKA (0.54) | HRH3SLC16A3CHKAHRH4 | |
| SCHEMBL21565624 | 0.85 | HRH3 (0.53) | HRH3SLC16A3ACHEKCNH2HRH4 | |
| SCHEMBL21565728 | 0.85 | ROCK2 (0.49) | HRH3SLC16A3CHKAHRH4 | |
| SCHEMBL21565653 | 0.84 | ALDH1A1 (0.47) | HRH3SLC16A3CHKAKCNH2HRH4 | |
| SCHEMBL21565727 | 0.84 | HRH3 (0.56) | HRH3ACHEHRH4 | |
| SCHEMBL21565737 | 0.84 | CHKA (0.60) | HRH3SLC16A3CHKA | |
| SCHEMBL23134809 | 0.81 | SLC16A3 (0.44) | HRH3SLC16A3CHKAKCNH2HRH4 | |
| SCHEMBL21565731 | 0.81 | SLC16A3 (0.44) | HRH3SLC16A3CHKAKCNH2HRH4 | |
| SCHEMBL23134796 | 0.81 | SLC16A3 (0.44) | HRH3SLC16A3CHKAKCNH2HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-3790879-B1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| WO-2019215316-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340150-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | HRH3 2001/4885SLC16A3 3/4885MAP4K4 490/4885 |
| US-20240217980-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ABCC4, ABCB1, SLC16A3 | HRH3 2001/4885SLC16A3 3/4885MAP4K4 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.